Punch & Associates Investment Management Inc. Purchases Shares of 2,058,089 MiMedx Group, Inc $MDXG

Punch & Associates Investment Management Inc. purchased a new stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,058,089 shares of the company’s stock, valued at approximately $7,924,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MDXG. SkyView Investment Advisors LLC grew its holdings in MiMedx Group by 3.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after buying an additional 3,032 shares in the last quarter. Rafferty Asset Management LLC raised its stake in MiMedx Group by 4.6% during the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after acquiring an additional 3,064 shares in the last quarter. Aviva PLC boosted its position in MiMedx Group by 4.7% during the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock worth $482,000 after acquiring an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the period. Finally, AQR Capital Management LLC boosted its position in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after acquiring an additional 4,296 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Trading Up 1.8%

NASDAQ:MDXG opened at $4.42 on Thursday. The stock has a market cap of $644.26 million, a PE ratio of 110.53 and a beta of 1.45. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The stock’s 50-day moving average is $4.15 and its two-hundred day moving average is $4.10.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The firm had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. As a group, equities research analysts forecast that MiMedx Group, Inc will post -0.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on MDXG shares. Weiss Ratings reissued a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Citizens Jmp cut their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Seaport Research Partners lowered shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Finally, Raymond James Financial set a $8.00 target price on shares of MiMedx Group in a research report on Monday, August 17th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average target price of $8.43.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.